NCT04804813View on ClinicalTrials.gov

Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

CompletedOBSERVATIONAL
Enrollment

388

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

July 25, 2024

Study Completion Date

July 25, 2024

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Cabozantinib

Cabozantinib tablets

Trial Locations (1)

Unknown

Takeda Selected Site, Tokyo

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT04804813 - Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter